Filing Flows › Comparisons › HRTX vs ATNM
Heron Therapeutics vs Actinium Pharmaceuticals: HRTX and ATNM compared
Heron Therapeutics is the larger company: $35.2M of revenue in its latest quarter (Q3 2026) against $35.0M for Actinium Pharmaceuticals (Q2 2026). Actinium Pharmaceuticals is more profitable, with an operating margin of 78.8% against -4.7%.
Where the money goes: HRTX and ATNM
Heron Therapeutics (HRTX) · Q3 2026
Heron Therapeutics, Q3 2026: revenue $35.2M (-8% year over year), operating margin -4.7%, net loss $5.0M, operating cash flow −$794K. The chart follows the revenue to costs, profit and cash.
Actinium Pharmaceuticals (ATNM) · Q2 2026
Actinium Pharmaceuticals, Q2 2026: revenue $35.0M, operating margin 78.8%, net earnings $27.9M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
| Heron Therapeutics (HRTX) | Actinium Pharmaceuticals (ATNM) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $35.2M | $35.0M |
| Revenue growth, Y/Y | -8% | — |
| Operating margin | -4.7% | 78.8% |
| Net earnings | −$5.0M | $27.9M |
| Net margin | -14.2% | 79.7% |
| Operating cash flow | −$794K | −$5.2M |
Where the revenue comes from
Heron Therapeutics
- CINVANTI: $20.0M (57%)
- ZYNRELEF: $10.6M (30%)
- Aponvie: $4.5M (13%)
- SUSTOL: $152K (0%)
Questions
Which is bigger, Heron Therapeutics or Actinium Pharmaceuticals?
Heron Therapeutics is the larger company: $35.2M of revenue in its latest quarter (Q3 2026) against $35.0M for Actinium Pharmaceuticals (Q2 2026).
Is Heron Therapeutics or Actinium Pharmaceuticals growing faster?
Actinium Pharmaceuticals is more profitable, with an operating margin of 78.8% against -4.7%.
More: Heron Therapeutics earnings · how Heron Therapeutics makes money · Actinium Pharmaceuticals earnings · how Actinium Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Aug 7, 2026). Fiscal quarters can end on different dates. Not investment advice.